drugset / Trial / NCT07502560
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
Phase 4
Recruiting
33609 enrolled
GlaxoSmithKline
Dr Arto Palmu · collabFinnish Vaccine Research; · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2030-04-01
- Completion
- 2037-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |